Figure 1.
Percentages of CD patients achieving clinical remission and endoscopic remission: (a) comparison of early UST use versus late UST use in overall enrolled patients; (b) comparison of <6 months versus 6–24 months in patients with early UST use; (c) comparison of early UST use versus late UST use in patients without a history of intestinal surgery; (d) comparison of early UST use versus late UST use in patients without prior exposure to biologics.
CD, Crohn’s disease; UST, Ustekinumab.